See more : Tekcore Co., Ltd (3339.TWO) Income Statement Analysis – Financial Results
Complete financial analysis of PhaseRx, Inc. (PZRXQ) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of PhaseRx, Inc., a leading company in the Biotechnology industry within the Healthcare sector.
- The Hilliard Corporation (HLRD) Income Statement Analysis – Financial Results
- Polylink Polymers (India) Limited (POLYLINK.BO) Income Statement Analysis – Financial Results
- GOME Retail Holdings Limited (0493.HK) Income Statement Analysis – Financial Results
- Allreal Holding AG (0QPD.L) Income Statement Analysis – Financial Results
- Proliance International, Inc. (PLNTQ) Income Statement Analysis – Financial Results
PhaseRx, Inc. (PZRXQ)
About PhaseRx, Inc.
PhaseRx, Inc., a biopharmaceutical company, engages in developing a portfolio of products for the treatment of inherited enzyme deficiencies in the liver using intracellular enzyme replacement therapy. The company develops its products based on its proprietary Hybrid mRNA technology platform, which allows the synthesis of missing enzyme inside the cell. Its therapeutic urea cycle disorder programs under development include PRX-OTC to treat ornithine transcarbamylase deficiency; PRX-ASL to treat argininosuccinate lyase deficiency; and PRX-ASS1 to treat argininosuccinate synthetase deficiency. The company was incorporated in 2006 and is headquartered in Seattle, Washington.
| Metric | 2022 | 2021 | 2020 | 2019 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|
| Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 375.00K | 1.20M |
| Cost of Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 375.00K | 1.20M |
| Gross Profit Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 100.00% | 100.00% |
| Research & Development | 0.00 | 0.00 | 0.00 | 0.00 | 6.66M | 4.88M | 4.86M |
| General & Administrative | 0.00 | 0.00 | 0.00 | 0.00 | 4.15M | 1.30M | 1.93M |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 7.52M | 0.00 | 0.00 |
| SG&A | 0.00 | 0.00 | 0.00 | 0.00 | 11.67M | 1.30M | 1.93M |
| Other Expenses | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Operating Expenses | 0.00 | 0.00 | 0.00 | 0.00 | 18.33M | 6.18M | 6.79M |
| Cost & Expenses | 0.00 | 0.00 | 0.00 | 0.00 | 18.33M | 6.18M | 6.79M |
| Interest Income | 0.00 | 0.00 | 0.00 | 0.00 | 61.00K | 0.00 | 0.00 |
| Interest Expense | 0.00 | 0.00 | 0.00 | 0.00 | 2.06M | 1.65M | 1.37M |
| Depreciation & Amortization | 228.49K | 236.56K | 206.30K | 171.86K | 136.00K | 331.00K | 512.00K |
| EBITDA | 0.00 | 0.00 | 0.00 | 0.00 | -17.94M | -5.40M | -4.97M |
| EBITDA Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | -1,460.27% | -423.25% |
| Operating Income | 0.00 | 0.00 | 0.00 | 0.00 | -18.33M | -5.81M | -5.59M |
| Operating Income Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | -1,548.53% | -465.92% |
| Total Other Income/Expenses | 0.00 | 0.00 | 0.00 | 0.00 | -1.81M | -1.57M | -1.26M |
| Income Before Tax | 0.00 | 0.00 | 0.00 | 0.00 | -20.14M | -7.38M | -6.85M |
| Income Before Tax Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | -1,967.20% | -570.75% |
| Income Tax Expense | 0.00 | 0.00 | 0.00 | 0.00 | 1.92M | 1.65M | 1.37M |
| Net Income | 0.00 | 0.00 | 0.00 | 0.00 | -20.14M | -7.38M | -6.85M |
| Net Income Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | -1,967.20% | -570.75% |
| EPS | 0.00 | 0.00 | 0.00 | 0.00 | -2.68 | -0.94 | -1.16 |
| EPS Diluted | 0.00 | 0.00 | 0.00 | 0.00 | -2.68 | -0.94 | -1.16 |
| Weighted Avg Shares Out | 0.00 | 0.00 | 0.00 | 0.00 | 7.52M | 7.88M | 5.90M |
| Weighted Avg Shares Out (Dil) | 0.00 | 0.00 | 0.00 | 0.00 | 7.52M | 7.88M | 5.90M |
Source: https://incomestatements.info
Category: Stock Reports